GlassScriptPhysician profile
Gregory N Lervick
NPI 1881701829
$7,852.32
in general payments reported to CMS, 2019-2025
11 companies · $1,977 in 2025
The $1,977 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $638 · 2021: $357 · 2022: $108 · 2023: $182 · 2024: $4,591 · 2025: $1,977.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $5,172 · Food and Beverage: $1,579.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $5,171.53 |
| Food and Beverage | $1,578.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medacta USA, INC. | $6,144.49 | 2023-2025 | Primary Shoulder, Gmk Sphere, Reverse Shoulder |
| Gemini Medical LLC | $488.00 | 2020 | |
| Exactech, INC. | $392.99 | 2020-2022 | |
| Anika Therapeutics, INC. | $221.29 | 2021 | |
| Smith+Nephew, INC. | $170.33 | 2024 | Bioinductive Implant With Arthroscopic Delivery System - Medium |
| Depuy Synthes Sales INC. | $147.01 | 2023-2025 | Inhance, Dynacord |
| Stryker Corporation | $135.07 | 2025 | Blueprint Patient Specific Instrumentation, Aequalis Reversed II, Aequalis Perform |
| Shoulder Innovations, INC. | $105.62 | 2025 | Inset System |
| Foundation Medical, LLC | $32.95 | 2024 | |
| Avanos Medical | $14.57 | 2023 | Grpro 2.1 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$446,986.01 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Lervick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.